PTX3 and coronary artery disorder: The results of the present study were similar to those of a comparison of atorvastatin (10 mg/day) with atorvastatin (10 mg/day) combined with ezetimibe (10 mg/day) in patients with CAD in that the combination significantly decreased hs-CRP, but not PTX3[37].